Ginkgo Bioworks (NYSE:DNA) Announces Earnings Results

Ginkgo Bioworks (NYSE:DNA) released its earnings results on Tuesday. The company reported ($1.82) EPS for the quarter, missing analysts’ consensus estimates of ($1.45) by ($0.37), Zacks reports. Ginkgo Bioworks had a negative net margin of 298.78% and a negative return on equity of 58.54%. Ginkgo Bioworks updated its FY 2025 guidance to EPS.

Ginkgo Bioworks Stock Performance

Shares of NYSE DNA traded down $0.10 during midday trading on Tuesday, reaching $10.37. The company had a trading volume of 2,820,512 shares, compared to its average volume of 1,745,475. The company’s fifty day simple moving average is $11.50. The company has a market cap of $595.78 million, a PE ratio of -0.79 and a beta of 1.16. Ginkgo Bioworks has a one year low of $5.26 and a one year high of $64.40.

Ginkgo Bioworks Company Profile

Ginkgo Bioworks Holdings, Inc, together with its subsidiaries, develops platform for cell programming in the United States. Its platform is used to program cells to enable biological production of products, such as novel therapeutics, food ingredients, and chemicals derived from petroleum. It serves pharma and biotech, agriculture, industrial and environment, food and nutrition, consumer and technology, and government and defense industries.